Please ensure Javascript is enabled for purposes of website accessibility

Influential Hydroxychloroquine COVID-19 Study Retracted by Authors

By Eric Volkman – Jun 5, 2020 at 6:10PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The data used in the study could not be verified by independent auditors.

An influential study measuring the efficacy and risks of the antimalarial drug hydroxychloroquine as a treatment for COVID-19 has been retracted at the request of its authors. It was published last month in prominent medical journal The Lancet.

The authors asked for the retraction because, after questions were raised about the data used in the research, independent auditors were denied access to the information required to verify that data. The study utilized data from a privately held healthcare analytics company, Surgisphere, which turned away the auditors.

Coronavirus in close-up.

Image source: Getty Images.

The study's authors said that their analysis of the data showed that  hydroxychloroquine use by COVID-19 patients led to a higher risk of serious side effects or death. This finding had a major impact, shifting the medical community's hopes away from the drug as a potential treatment for the disease caused by the SARS-CoV-2 coronavirus.

Based on that analysis, the World Health Organization (WHO) briefly halted clinical trials it was conducting on hydroxychloroquine. Subsequently, multinational pharmaceutical company Sanofi (SNY 0.05%) stopped supplying it for patients participating in its own trials.

In a retraction published in The Lancet, the study's authors wrote: "We can never forget the responsibility we have as researchers to scrupulously ensure that we rely on data sources that adhere to our high standards. Based on this development, we can no longer vouch for the veracity of the primary data sources."

Sanofi hasn't commented on the retraction. The company continues to be active particularly in the hunt for a COVID-19 vaccine. It is leveraging its considerable vaccine development experience in collaboration with U.S. government health authorities in a program aimed at preventing the disease.

On Friday, Sanofi's shares inched up by 0.3%, well behind the gains of the broader stock market.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sanofi Stock Quote
$38.02 (0.05%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.